Compass Therapeutics Valuation
| CMPX Stock | USD 5.19 -0.40 -7.16% |
Currently, Compass Therapeutics appears to be undervalued. Compass Therapeutics has a last-minute Real Value of $7.11 per share. The last-minute price of Compass Therapeutics is $5.19. Our model determines the value of Compass Therapeutics from analyzing Compass Therapeutics fundamentals such as Return On Equity of -0.41, current valuation of 714.85 M, and Shares Owned By Insiders of 11.14 % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Compass Therapeutics' valuation include:
Price Book 4.4123 | Enterprise Value | Enterprise Value Ebitda -8.92 | Price Sales 269.2826 | Enterprise Value Revenue 109.2827 |
Undervalued
Today
Please note that Compass Therapeutics' price fluctuation is Slightly Elevated at this time. Calculation of the real value of Compass Therapeutics is based on 3 months time horizon. Increasing Compass Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Compass Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Compass Stock. However, Compass Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.19 | Real 7.11 | Target 13.64 | Hype 5.17 | Naive 5.41 |
The real or intrinsic value of Compass Therapeutics represents the present value of its expected future cash flows and earnings. Approaches for estimating Compass Therapeutics' intrinsic value range from fundamental DCF models to relative valuation benchmarks.
Quantifying the upside and downside potential of Compass Therapeutics helps investors set realistic expectations. The value of Compass stock in a portfolio context is shaped by both its intrinsic metrics and current market dynamics.Valuation models applied to Compass Therapeutics range from simple P/E comparisons to multi-stage DCF models. The choice of method should match the visibility and stability of Compass Therapeutics' earnings and cash flows.
Cash is showing structural movement consistent with a pulling back trend. The preceding year’s Cash stood at 30.64 Million. As of last month (February 2026), Accounts Payable is projected to grow to approximately 2.1 MCompass Therapeutics Cash | 40.77 Million |
Compass Therapeutics Total Value Analysis
From a capital-structure perspective, Compass Therapeutics is being framed with enterprise value of 714.85 M, market capitalization of 923.1 M, debt obligations near 9.83 M, and cash resources of 132.02 M. That snapshot should be treated as one valuation lens rather than as final proof of fair value because the interpretation can shift quickly when financing assumptions change.| Takeover Price | Market Cap | Debt Obligations | Cash |
714.85 M | 923.1 M | 9.83 M | 132.02 M |
Compass Therapeutics Asset Utilization
One of the ways to look at asset utilization of Compass is to check how much profit was generated for every dollar of assets it reports. Compass Therapeutics has a negative application of assets of -0.25%, losing $0.002529 for each dollar of assets held by the company. Inefficient asset utilization attests that the company is being less capable with each dollar of assets it has. Strictly speaking, asset utilization of Compass Therapeutics shows how inefficient it operates for each dollar spent on its assets.Macro event markers
Compass Therapeutics Profitability Analysis
Based on Compass Therapeutics' profitability indicators, Compass Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in April. Profitability indicators assess Compass Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2019-06-30 | Previous Quarter -14.3 M | Current Value -15.7 M | Quarterly Volatility 9.4 M |
Macro event markers
Profitability analysis for Compass Therapeutics works best when investors review the financial ratios and fundamental drivers that explain how efficiently the business converts revenue, assets, and operating inputs into earnings. These profitability indicators help investors judge how well Compass Therapeutics uses its assets to create earnings power and long-term shareholder value.
Compass Therapeutics Earnings per Share Projection vs Actual
By analyzing Compass Therapeutics' earnings estimates, investors can diagnose trend shifts in analyst expectations and compare EPS projections across timeframes. EPS is most informative when read together with margin stability and cash-flow conversion. EPS forecast analysis for Compass Therapeutics is useful, but investors should remember that consensus numbers often reflect a normalized estimate rather than a full reconstruction of every accounting detail. Compass Therapeutics is projected to generate -0.103075 in earnings per share on 31st of December 2026. Future earnings-per-share expectations are often a key input when investors test valuation assumptions and momentum into the next quarter.Macro event markers
Compass Therapeutics Ownership Allocation
The majority of Compass Therapeutics' outstanding shares are owned by institutions. This level of institutional concentration typically reflects the stock's inclusion in major indices, consistent liquidity, and long-term investment attractiveness for funds managing assets on behalf of pensions, endowments, and other institutional clients. With institutions controlling the majority of the float, changes in quarterly 13F filings can provide meaningful signals about shifts in professional investor sentiment. The ownership breakdown for Compass Therapeutics shows approximately 88% institutional, 11% insider, and 1% public.Compass Therapeutics Profitability Analysis
Net Loss for the year was -66.49 M with profit before overhead, payroll, taxes, and interest of 0.Valuation analysis for Compass Therapeutics should be treated as an ongoing process rather than a one-time answer, especially when investors are trying to understand how the market is pricing this stock. The practical goal is to understand how new information changes the valuation case, not to defend one static estimate after conditions move.
Valuation Framework, Methodology & Assumptions
Compass Therapeutics is a small-cap equity in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care categories. Growth expectations are weighed against macro conditions. Exposure to macroeconomic shifts appears broadly consistent with overall market behavior. Compass Therapeutics currently trades at P/B of 4.41, P/S of 269.28, enterprise value of 714.85 M.
Reported values for Compass Therapeutics are derived from periodic company reporting and market reference feeds and then standardized by Macroaxis analytics. Analyst inputs may be included when coverage is available. Refresh times depend on source availability. Valuation outputs are model-derived and depend on published assumptions and reference inputs.
This content is curated and reviewed by:
Ellen Johnson - Member of Macroaxis Editorial BoardCompass Therapeutics Current Valuation Indicators
Valuation work on Compass Therapeutics becomes more reliable when investors compare several lenses at once, including market value, enterprise value. revenue scale, and expected cash-flow durability. The better valuation questions are comparative: what is the market paying for each dollar of revenue, profit, and asset base, and is that premium justified?
Popular Tools for Compass Stock analysis
| CEOs Directory Screen CEOs from public companies around the world | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Holdings Check your current holdings and cash position to determine if your portfolio needs rebalancing | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |